BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lichtenstein GR, Diamond RH, Wagner CL, Fasanmade AA, Olson AD, Marano CW, Johanns J, Lang Y, Sandborn WJ. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther. 2009;30:210-226. [PMID: 19392858 DOI: 10.1111/j.1365-2036.2009.04027.x] [Cited by in Crossref: 145] [Cited by in F6Publishing: 131] [Article Influence: 12.1] [Reference Citation Analysis]
Number Citing Articles
1 Papamichael K, Mantzaris GJ, Peyrin-Biroulet L. A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn's disease. Expert Opin Drug Saf 2016;15:493-501. [PMID: 26799429 DOI: 10.1517/14740338.2016.1145653] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
2 Sandborn WJ. The Future of Inflammatory Bowel Disease Therapy: Where Do We Go from Here? Dig Dis 2012;30:140-4. [DOI: 10.1159/000342742] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
3 Bortlik M, Duricova D, Malickova K, Machkova N, Bouzkova E, Hrdlicka L, Komarek A, Lukas M. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease. J Crohns Colitis. 2013;7:736-743. [PMID: 23200919 DOI: 10.1016/j.crohns.2012.10.019] [Cited by in Crossref: 162] [Cited by in F6Publishing: 152] [Article Influence: 18.0] [Reference Citation Analysis]
4 Konidari A, Matary WE. Use of thiopurines in inflammatory bowel disease: Safety issues. World J Gastrointest Pharmacol Ther 2014; 5(2): 63-76 [PMID: 24868487 DOI: 10.4292/wjgpt.v5.i2.63] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
5 Melmed GY, Spiegel BM, Bressler B, Cheifetz AS, Devlin SM, Harrell LE, Irving PM, Jones J, Kaplan GG, Kozuch PL. The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn’s disease: one size does not fit all. Clin Gastroenterol Hepatol. 2010;8:655-659. [PMID: 20451665 DOI: 10.1016/j.cgh.2010.04.023] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
6 Dumitrescu G, Amiot A, Seksik P, Baudry C, Stefanescu C, Gagniere C, Allez M, Cosnes J, Bouhnik Y. The outcome of infliximab dose doubling in 157 patients with ulcerative colitis after loss of response to infliximab. Aliment Pharmacol Ther 2015;42:1192-9. [DOI: 10.1111/apt.13393] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
7 Dulai PS, Siegel CA, Peyrin-Biroulet L. Anti-tumor necrosis factor-α monotherapy versus combination therapy with an immunomodulator in IBD. Gastroenterol Clin North Am 2014;43:441-56. [PMID: 25110252 DOI: 10.1016/j.gtc.2014.05.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
8 Cozijnsen MA, Escher JC, Griffiths A, Turner D, de Ridder L. Benefits and Risks of Combining Anti-tumor Necrosis Factor with Immunomodulator Therapy in Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015;21:951-961. [PMID: 25723615 DOI: 10.1097/mib.0000000000000245] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 3.2] [Reference Citation Analysis]
9 Scott FI, Luo M, Shah Y, Lasch K, Vajravelu RK, Mamtani R, Fennimore B, Gerich ME, Lewis JD. Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis. J Crohns Colitis 2020;14:575-87. [PMID: 31901085 DOI: 10.1093/ecco-jcc/jjz212] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
10 Rostholder E, Ahmed A, Cheifetz AS, Moss AC. Outcomes after escalation of infliximab therapy in ambulatory patients with moderately active ulcerative colitis. Aliment Pharmacol Ther. 2012;35:562-567. [PMID: 22239070 DOI: 10.1111/j.1365-2036.2011.04986.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 3.3] [Reference Citation Analysis]
11 Yan X, Zhu M, Feng Q, Yan Y, Peng J, Xu X, Xu A, Ran Z. Evaluating the effectiveness of infliximab on perianal fistulizing Crohn's disease by magnetic resonance imaging. Gastroenterol Rep (Oxf) 2019;7:50-6. [PMID: 30792866 DOI: 10.1093/gastro/goy036] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Moss AC, Brinks V, Carpenter JF. Review article: immunogenicity of anti-TNF biologics in IBD - the role of patient, product and prescriber factors. Aliment Pharmacol Ther. 2013;38:1188-1197. [PMID: 24118102 DOI: 10.1111/apt.12507] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 7.1] [Reference Citation Analysis]
13 Strik AS, Bots SJA, D’haens G, Löwenberg M. Optimization of anti-TNF therapy in patients with Inflammatory Bowel Disease. Expert Review of Clinical Pharmacology 2015;9:429-39. [DOI: 10.1586/17512433.2016.1133288] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 6.6] [Reference Citation Analysis]
14 Cohen BL, Torres J, Colombel JF. Immunosuppression in inflammatory bowel disease: how much is too much? Curr Opin Gastroenterol 2012;28:341-8. [PMID: 22573191 DOI: 10.1097/MOG.0b013e328354567f] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
15 Kim YJ, Kim JW, Lee CK, Park HJ, Shim JJ, Jang JY, Dong SH, Kim HJ, Kim BH, Chang YW. [Clinical outcome of treatment with infliximab in Crohn's disease: a single-center experience]. Korean J Gastroenterol 2013;61:270-8. [PMID: 23756669 DOI: 10.4166/kjg.2013.61.5.270] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
16 Cabriada JL, Vera I, Domènech E, Barreiro-de Acosta M, Esteve M, Gisbert JP, Panés J, Gomollón F; Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU). [Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on the use of anti-tumor necrosis factor drugs in inflammatory bowel disease]. Gastroenterol Hepatol 2013;36:127-46. [PMID: 23433780 DOI: 10.1016/j.gastrohep.2013.01.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 3.1] [Reference Citation Analysis]
17 Ha C, Maser EA, Kornbluth A. Clinical presentation and outcomes of inflammatory bowel disease patients admitted to the intensive care unit. J Clin Gastroenterol. 2013;47:485-490. [PMID: 23388843 DOI: 10.1097/mcg.0b013e318275d981] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
18 Tozer PJ, Burling D, Gupta A, Phillips RKS, Hart AL. Review article: medical, surgical and radiological management of perianal Crohn’s fistulas: Review: multidisciplinary management of perianal Crohn’s fistulas. Alimentary Pharmacology & Therapeutics 2011;33:5-22. [DOI: 10.1111/j.1365-2036.2010.04486.x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 43] [Article Influence: 5.4] [Reference Citation Analysis]
19 Baert F, Drobne D, Gils A, Vande Casteele N, Hauenstein S, Singh S, Lockton S, Rutgeerts P, Vermeire S. Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy. Clin Gastroenterol Hepatol. 2014;12:1474-1481.e2; quiz e91. [PMID: 24486408 DOI: 10.1016/j.cgh.2014.01.033] [Cited by in Crossref: 86] [Cited by in F6Publishing: 77] [Article Influence: 12.3] [Reference Citation Analysis]
20 Nielsen OH, Bjerrum JT, Seidelin JB, Nyberg C, Ainsworth M. Biological treatment of Crohn’s disease. Dig Dis. 2012;30 Suppl 3:121-133. [PMID: 23295703 DOI: 10.1159/000342738] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
21 Lobatón T, Ferrante M, Rutgeerts P, Ballet V, Van Assche G, Vermeire S. Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease. Aliment Pharmacol Ther 2015;42:441-51. [PMID: 26104047 DOI: 10.1111/apt.13294] [Cited by in Crossref: 90] [Cited by in F6Publishing: 79] [Article Influence: 15.0] [Reference Citation Analysis]
22 Everett SM, Hamlin PJ. Evidence-based use of anti-TNFα therapy in Crohn's disease; where are we in 2011? Frontline Gastroenterol 2011;2:144-50. [PMID: 28839599 DOI: 10.1136/fg.2010.003566] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
23 Afif W, Loftus EV, Faubion WA, Kane SV, Bruining DH, Hanson KA, Sandborn WJ. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105:1133-1139. [PMID: 20145610 DOI: 10.1038/ajg.2010.9] [Cited by in Crossref: 356] [Cited by in F6Publishing: 331] [Article Influence: 32.4] [Reference Citation Analysis]
24 Christian KE, Russman KM, Rajan DP, Barr EA, Cross RK. Gender Differences and Other Factors Associated with Weight Gain Following Initiation of Infliximab: A Post Hoc Analysis of Clinical Trials. Inflammatory Bowel Diseases 2020;26:125-31. [DOI: 10.1093/ibd/izz133] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Bressler B, Marshall JK, Bernstein CN, Bitton A, Jones J, Leontiadis GI, Panaccione R, Steinhart AH, Tse F, Feagan B; Toronto Ulcerative Colitis Consensus Group. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology. 2015;148:1035-1058.e3. [PMID: 25747596 DOI: 10.1053/j.gastro.2015.03.001] [Cited by in Crossref: 211] [Cited by in F6Publishing: 179] [Article Influence: 35.2] [Reference Citation Analysis]
26 Bouguen G, Siproudhis L, Gizard E, Wallenhorst T, Billioud V, Bretagne JF, Bigard MA, Peyrin-Biroulet L. Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab. Clin Gastroenterol Hepatol. 2013;11:975-81.e1-4. [PMID: 23376316 DOI: 10.1016/j.cgh.2012.12.042] [Cited by in Crossref: 105] [Cited by in F6Publishing: 96] [Article Influence: 13.1] [Reference Citation Analysis]
27 Osterman MT, Haynes K, Delzell E, Zhang J, Bewtra M, Brensinger CM, Chen L, Xie F, Curtis JR, Lewis JD. Effectiveness and Safety of Immunomodulators With Anti-Tumor Necrosis Factor Therapy in Crohn’s Disease. Clin Gastroenterol Hepatol. 2015;13:1293-1301.e5; quiz e70, e72. [PMID: 25724699 DOI: 10.1016/j.cgh.2015.02.017] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 8.0] [Reference Citation Analysis]
28 Annese V, Duricova D, Gower-rousseau C, Jess T, Langholz E. Impact of New Treatments on Hospitalisation, Surgery, Infection, and Mortality in IBD: a Focus Paper by the Epidemiology Committee of ECCO. ECCOJC 2016;10:216-25. [DOI: 10.1093/ecco-jcc/jjv190] [Cited by in Crossref: 70] [Cited by in F6Publishing: 59] [Article Influence: 11.7] [Reference Citation Analysis]
29 Pugliese D, Guidi L, Ferraro PM, Marzo M, Felice C, Celleno L, Landi R, Andrisani G, Pizzolante F, De Vitis I, Papa A, Rapaccini GL, Armuzzi A. Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study. Aliment Pharmacol Ther 2015;42:880-8. [DOI: 10.1111/apt.13352] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 8.5] [Reference Citation Analysis]
30 Kim JY, Lee Y, Choe BH, Kang B. Factors Associated with the Immunogenicity of Anti-Tumor Necrosis Factor Agents in Pediatric Patients with Inflammatory Bowel Disease. Gut Liver 2021;15:588-98. [PMID: 33024062 DOI: 10.5009/gnl20134] [Reference Citation Analysis]
31 Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG Clinical Guideline: Management of Crohn's Disease in Adults. Am J Gastroenterol. 2018;113:481-517. [PMID: 29610508 DOI: 10.1038/ajg.2018.27] [Cited by in Crossref: 390] [Cited by in F6Publishing: 303] [Article Influence: 130.0] [Reference Citation Analysis]
32 Oussalah A, Chevaux JB, Fay R, Sandborn WJ, Bigard MA, Peyrin-Biroulet L. Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy. Am J Gastroenterol. 2010;105:1142-1149. [PMID: 20389296 DOI: 10.1038/ajg.2010.158] [Cited by in Crossref: 70] [Cited by in F6Publishing: 59] [Article Influence: 6.4] [Reference Citation Analysis]
33 Pękala A, Filip R, Aebisher D. Anti-Drug Antibodies in Patients with Inflammatory Bowel Diseases Treated with Biosimilar Infliximab: A Prospective Cohort Study. J Clin Med 2021;10:2653. [PMID: 34208676 DOI: 10.3390/jcm10122653] [Reference Citation Analysis]
34 Jairath V, Zou GY, Parker CE, MacDonald JK, AlAmeel T, Al Beshir M, Almadi MA, Al-Taweel T, Atkinson NS, Biswas S, Chapman T, Dulai PS, Glaire MA, Hoekman DR, Koutsoumpas A, Minas E, Mosli MH, Samaan M, Khanna R, Travis S, D'Haens G, Sandborn WJ, Feagan BG. Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis. Cochrane Database Syst Rev 2017;9:CD011572. [PMID: 28886205 DOI: 10.1002/14651858.CD011572.pub2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
35 Flamant M, Paul S, Roblin X. Golimumab for the treatment of ulcerative colitis. Expert Opin Biol Ther 2017;17:879-86. [PMID: 28472597 DOI: 10.1080/14712598.2017.1327576] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
36 Nattiv R, Wojcicki JM, Garnett EA, Gupta N, Heyman MB. High-dose infliximab for treatment of pediatric ulcerative colitis: A survey of clinical practice. World J Gastroenterol 2012; 18(11): 1229-1234 [PMID: 22468086 DOI: 10.3748/wjg.v18.i11.1229] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
37 Shi JH, Luo L, Chen XL, Pan YP, Zhang Z, Fang H, Chen Y, Chen WD, Cao Q. Real-world cost-effectiveness associated with infliximab maintenance therapy for moderate to severe Crohn’s disease in China. World J Gastroenterol 2020; 26(41): 6455-6474 [PMID: 33244205 DOI: 10.3748/wjg.v26.i41.6455] [Reference Citation Analysis]
38 Larkin JM, Ferguson TR, Pickering LM, Edmonds K, James MG, Thomas K, Banerji U, Berns B, de Boer C, Gore ME. A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma. Br J Cancer 2010;103:1149-53. [PMID: 20842130 DOI: 10.1038/sj.bjc.6605889] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
39 Qiu Y, Mao R, Chen B, Zhang S, Guo J, He Y, Zeng Z, Ben-horin S, Chen M. Effects of Combination Therapy With Immunomodulators on Trough Levels and Antibodies Against Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease: A Meta-analysis. Clinical Gastroenterology and Hepatology 2017;15:1359-1372.e6. [DOI: 10.1016/j.cgh.2017.02.005] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 7.5] [Reference Citation Analysis]
40 Vande Casteele N, Mould DR, Coarse J, Hasan I, Gils A, Feagan B, Sandborn WJ. Accounting for Pharmacokinetic Variability of Certolizumab Pegol in Patients with Crohn's Disease. Clin Pharmacokinet 2017;56:1513-23. [PMID: 28353055 DOI: 10.1007/s40262-017-0535-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
41 Falaiye TO, Mitchell KR, Lu Z, Saville BR, Horst SN, Moulton DE, Schwartz DA, Wilson KT, Rosen MJ. Outcomes following infliximab therapy for pediatric patients hospitalized with refractory colitis-predominant IBD. J Pediatr Gastroenterol Nutr 2014;58:213-9. [PMID: 24048170 DOI: 10.1097/MPG.0b013e3182a98df2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
42 Jacob EM, Borah A, Pillai SC, Kumar DS. Inflammatory Bowel Disease: The Emergence of New Trends in Lifestyle and Nanomedicine as the Modern Tool for Pharmacotherapy. Nanomaterials (Basel) 2020;10:E2460. [PMID: 33316984 DOI: 10.3390/nano10122460] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
43 Osterman MT, Sandborn WJ, Colombel JF, Robinson AM, Lau W, Huang B, Pollack PF, Thakkar RB, Lewis JD. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease. Gastroenterology. 2014;146:941-949. [PMID: 24361468 DOI: 10.1053/j.gastro.2013.12.025] [Cited by in Crossref: 125] [Cited by in F6Publishing: 109] [Article Influence: 15.6] [Reference Citation Analysis]
44 Desai A, Zator ZA, de Silva P, Nguyen DD, Korzenik J, Yajnik V, Ananthakrishnan AN. Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis 2013;19:309-15. [PMID: 22605668 DOI: 10.1002/ibd.23026] [Cited by in Crossref: 88] [Cited by in F6Publishing: 78] [Article Influence: 11.0] [Reference Citation Analysis]
45 Scott FI, Shah Y, Lasch K, Luo M, Lewis JD. Assessing the Optimal Position for Vedolizumab in the Treatment of Ulcerative Colitis: A Simulation Model. Inflammatory Bowel Diseases 2018;24:286-95. [DOI: 10.1093/ibd/izx045] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
46 Yarur AJ, Abreu MT, Deshpande AR, Kerman DH, Sussman DA. Therapeutic drug monitoring in patients with inflammatory bowel disease. World J Gastroenterol 2014; 20(13): 3475-3484 [PMID: 24707130 DOI: 10.3748/wjg.v20.i13.3475] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 34] [Article Influence: 5.6] [Reference Citation Analysis]
47 Rieder F, Reinisch W. Thiopurines and the Natural Course of Crohn's Disease: Did We Finally Find the Right Therapeutic Target? American Journal of Gastroenterology 2014;109:1037-40. [DOI: 10.1038/ajg.2014.162] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
48 Lakatos PL, Kiss LS. Current status of thiopurine analogues in the treatment in Crohn's disease. World J Gastroenterol 2011; 17(39): 4372-4381 [PMID: 22110262 DOI: 10.3748/wjg.v17.i39.4372] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
49 Silva PSA, Nguyen DD, Sauk J, Korzenik J, Yajnik V, Ananthakrishnan AN. Long-term outcome of a third anti-TNF monoclonal antibody after the failure of two prior anti-TNFs in inflammatory bowel disease. Aliment Pharmacol Ther 2012;36:459-66. [DOI: 10.1111/j.1365-2036.2012.05214.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 4.1] [Reference Citation Analysis]
50 Ward MG, Irving PM, Sparrow MP. How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease? World J Gastroenterol 2015; 21(40): 11331-11342 [PMID: 26525434 DOI: 10.3748/wjg.v21.i40.11331] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
51 Thomas SS, Borazan N, Barroso N, Duan L, Taroumian S, Kretzmann B, Bardales R, Elashoff D, Vangala S, Furst DE. Comparative Immunogenicity of TNF Inhibitors: Impact on Clinical Efficacy and Tolerability in the Management of Autoimmune Diseases. A Systematic Review and Meta-Analysis. BioDrugs 2015;29:241-58. [DOI: 10.1007/s40259-015-0134-5] [Cited by in Crossref: 96] [Cited by in F6Publishing: 88] [Article Influence: 16.0] [Reference Citation Analysis]
52 Choi CH, Kim Y, Kim YS, Ye BD, Lee KM, Lee BI, Jung S, Kim WH, Lee H; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Guidelines for the Management of Ulcerative Colitis. Intest Res 2012;10:1. [DOI: 10.5217/ir.2012.10.1.1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 1.1] [Reference Citation Analysis]
53 Rahier JF. Prevention and management of infectious complications in IBD. Dig Dis. 2012;30:408-414. [PMID: 22796807 DOI: 10.1159/000338143] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
54 Colombel JF, Adedokun OJ, Gasink C, Gao LL, Cornillie FJ, D'Haens GR, Rutgeerts PJ, Reinisch W, Sandborn WJ, Hanauer SB. Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis. Clin Gastroenterol Hepatol. 2019;17:1525-1532.e1. [PMID: 30267864 DOI: 10.1016/j.cgh.2018.09.033] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 17.0] [Reference Citation Analysis]
55 Melmed GY, Kaplan GG, Sparrow MP, Velayos FS, Baidoo L, Bressler B, Cheifetz AS, Devlin SM, Irving PM, Jones J, Kozuch PL, Raffals LE, Siegel CA. Appropriateness of Combination Therapy for Patients With Inflammatory Bowel Diseases: One Size Still Does Not Fit All. Clin Gastroenterol Hepatol 2018;16:1829-31. [PMID: 29505910 DOI: 10.1016/j.cgh.2018.02.036] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
56 Raine T, Kennedy NA. Immunomodulator and Biologic Combination Therapy in IBD: The Debate That Just Won't Go Away? J Crohns Colitis 2020;14:1343-4. [PMID: 33016315 DOI: 10.1093/ecco-jcc/jjaa070] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Lee TW, Fedorak RN. Tumor necrosis factor-α monoclonal antibodies in the treatment of inflammatory bowel disease: clinical practice pharmacology. Gastroenterol Clin North Am. 2010;39:543-557. [PMID: 20951917 DOI: 10.1016/j.gtc.2010.08.018] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 3.1] [Reference Citation Analysis]
58 Archer R, Tappenden P, Ren S, Martyn-St James M, Harvey R, Basarir H, Stevens J, Carroll C, Cantrell A, Lobo A, Hoque S. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model. Health Technol Assess 2016;20:1-326. [PMID: 27220829 DOI: 10.3310/hta20390] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
59 Sultan KS, Berkowitz JC, Khan S. Combination therapy for inflammatory bowel disease. World J Gastrointest Pharmacol Ther 2017; 8(2): 103-113 [PMID: 28533919 DOI: 10.4292/wjgpt.v8.i2.103] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
60 Cottone M, Renna S, Orlando A, Mocciaro F. Medical management of Crohn's disease. Expert Opin Pharmacother. 2011;12:2505-2525. [PMID: 21988215 DOI: 10.1517/14656566.2011.609556] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
61 Choi CH, Kim YH, Kim YS, Ye BD, Lee KM, Lee BI, Jung SA, Kim WH, Lee H; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. [Guidelines for the management of ulcerative colitis]. Korean J Gastroenterol. 2012;59:118-140. [PMID: 22387836 DOI: 10.4166/kjg.2012.59.2.118] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
62 Afif W, Loftus EV. Safety profile of IBD therapeutics: infectious risks. Med Clin North Am. 2010;94:115-133. [PMID: 19944801 DOI: 10.1016/j.mcna.2009.08.016] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
63 Krieckaert CL, Bartelds GM, Lems WF, Wolbink GJ. The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review. Arthritis Res Ther 2010;12:217. [PMID: 21029481 DOI: 10.1186/ar3147] [Cited by in Crossref: 73] [Cited by in F6Publishing: 69] [Article Influence: 6.6] [Reference Citation Analysis]
64 Di Sabatino A, Liberato L, Marchetti M, Biancheri P, Corazza GR. Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease. Intern Emerg Med. 2011;6 Suppl 1:17-27. [PMID: 22009609 DOI: 10.1007/s11739-011-0673-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
65 Won HS, Park DI, Chon CU, Seok HS, Kim TW, Heo WJ, Lee CK, Eun CS, Han DS, Lee S. Comparison of Infliximab and Infliximab/Azathioprine for Maintenance Therapy in Korean Patients with Luminal Crohn's Disease. Intest Res 2011;9:189. [DOI: 10.5217/ir.2011.9.3.189] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
66 Lichtenstein L, Ron Y, Kivity S, Ben-Horin S, Israeli E, Fraser GM, Dotan I, Chowers Y, Confino-Cohen R, Weiss B. Infliximab-Related Infusion Reactions: Systematic Review. J Crohns Colitis. 2015;9:806-815. [PMID: 26092578 DOI: 10.1093/ecco-jcc/jjv096] [Cited by in Crossref: 97] [Cited by in F6Publishing: 70] [Article Influence: 16.2] [Reference Citation Analysis]
67 Hayes MJ, Stein AC, Sakuraba A. Comparison of efficacy, pharmacokinetics, and immunogenicity between infliximab mono- versus combination therapy in ulcerative colitis: Combination therapy for ulcerative colitis. J Gastroenterol Hepatol 2014;29:1177-85. [DOI: 10.1111/jgh.12517] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
68 Ma C, Huang V, Fedorak DK, Kroeker KI, Dieleman LA, Halloran BP, Fedorak RN. Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: A real life cohort study. Journal of Crohn's and Colitis 2014;8:1454-63. [DOI: 10.1016/j.crohns.2014.05.007] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 5.3] [Reference Citation Analysis]
69 Chen L, Xu CJ, Wu W, Ding BJ, Liu ZJ. Anti-TNF and immunosuppressive combination therapy is preferential to inducing clinical remission in patients with active inflammatory bowel disease: A systemic review and meta-analysis. J Dig Dis 2021;22:408-18. [PMID: 34048629 DOI: 10.1111/1751-2980.13026] [Reference Citation Analysis]
70 Volk N, Siegel CA. Defining Failure of Medical Therapy for Inflammatory Bowel Disease. Inflamm Bowel Dis 2019;25:74-7. [PMID: 30016434 DOI: 10.1093/ibd/izy238] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
71 Danese S, Colombel JF, Reinisch W, Rutgeerts PJ. Review article: infliximab for Crohn's disease treatment--shifting therapeutic strategies after 10 years of clinical experience. Aliment Pharmacol Ther 2011;33:857-69. [PMID: 21320139 DOI: 10.1111/j.1365-2036.2011.04598.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 5.6] [Reference Citation Analysis]
72 Kevans D, Murthy S, Mould DR, Silverberg MS. Accelerated Clearance of Infliximab is Associated With Treatment Failure in Patients With Corticosteroid-Refractory Acute Ulcerative Colitis. Journal of Crohn's and Colitis 2018;12:662-9. [DOI: 10.1093/ecco-jcc/jjy028] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
73 Singh UP, Singh NP, Singh B, Mishra MK, Nagarkatti M, Nagarkatti PS, Singh SR. Stem cells as potential therapeutic targets for inflammatory bowel disease. Front Biosci (Schol Ed). 2010;2:993-1008. [PMID: 20515838 DOI: 10.2741/s115] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
74 Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol 2013;108:40-7; quiz 48. [PMID: 23147525 DOI: 10.1038/ajg.2012.363] [Cited by in Crossref: 243] [Cited by in F6Publishing: 223] [Article Influence: 27.0] [Reference Citation Analysis]
75 Lin K, Mahadevan U. Pharmacokinetics of Biologics and the Role of Therapeutic Monitoring. Gastroenterology Clinics of North America 2014;43:565-79. [DOI: 10.1016/j.gtc.2014.05.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
76 Zwicker S, Martinez GL, Bosma M, Gerling M, Clark R, Majster M, Söderman J, Almer S, Boström EA. Interleukin 34: a new modulator of human and experimental inflammatory bowel disease. Clin Sci (Lond) 2015;129:281-90. [PMID: 25896238 DOI: 10.1042/CS20150176] [Cited by in Crossref: 53] [Cited by in F6Publishing: 26] [Article Influence: 8.8] [Reference Citation Analysis]
77 Armuzzi A, Pugliese D, Danese S, Rizzo G, Felice C, Marzo M, Andrisani G, Fiorino G, Sociale O, Papa A, De Vitis I, Rapaccini GL, Guidi L. Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission. Inflamm Bowel Dis. 2013;19:1065-1072. [PMID: 23448790 DOI: 10.1097/mib.0b013e3182802909] [Cited by in Crossref: 53] [Cited by in F6Publishing: 21] [Article Influence: 6.6] [Reference Citation Analysis]
78 Xu Z, Davis HM, Zhou H. Clinical impact of concomitant immunomodulators on biologic therapy: Pharmacokinetics, immunogenicity, efficacy and safety. J Clin Pharmacol 2015;55 Suppl 3:S60-74. [PMID: 25707965 DOI: 10.1002/jcph.380] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
79 Corica D, Romano C. Biological Therapy in Pediatric Inflammatory Bowel Disease: A Systematic Review. J Clin Gastroenterol. 2017;51:100-110. [PMID: 27636407 DOI: 10.1097/mcg.0000000000000696] [Cited by in Crossref: 27] [Cited by in F6Publishing: 6] [Article Influence: 6.8] [Reference Citation Analysis]
80 Christophorou D, Funakoshi N, Duny Y, Valats J, Bismuth M, Pineton De Chambrun G, Daures J, Blanc P. Systematic review with meta-analysis: infliximab and immunosuppressant therapy vs. infliximab alone for active ulcerative colitis. Aliment Pharmacol Ther 2015;41:603-12. [DOI: 10.1111/apt.13102] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
81 Kotlyar DS, Osterman MT, Diamond RH, Porter D, Blonski WC, Wasik M, Sampat S, Mendizabal M, Lin MV, Lichtenstein GR. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9:36-41.e1. [PMID: 20888436 DOI: 10.1016/j.cgh.2010.09.016] [Cited by in Crossref: 305] [Cited by in F6Publishing: 241] [Article Influence: 27.7] [Reference Citation Analysis]
82 Chaparro M, Guerra I, Muñoz-Linares P, Gisbert JP. Systematic review: antibodies and anti-TNF-α levels in inflammatory bowel disease. Aliment Pharmacol Ther 2012;35:971-86. [PMID: 22443153 DOI: 10.1111/j.1365-2036.2012.05057.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
83 Swoger JM, Regueiro M. Stopping, Continuing, or Restarting Immunomodulators and Biologics When an Infection or Malignancy Develops: . Inflammatory Bowel Diseases 2014;20:926-35. [DOI: 10.1097/mib.0000000000000002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
84 Ordás I, Feagan BG, Sandborn WJ. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2012;10:1079-1087; quiz e85-86. [PMID: 22813440 DOI: 10.1016/j.cgh.2012.06.032] [Cited by in Crossref: 148] [Cited by in F6Publishing: 132] [Article Influence: 16.4] [Reference Citation Analysis]
85 Ye BD, Yang SK, Shin SJ, Lee KM, Jang BI, Cheon JH, Choi CH, Kim YH, Lee H. [Guidelines for the management of Crohn’s disease]. Korean J Gastroenterol. 2012;59:141-179. [PMID: 22387837 DOI: 10.4166/kjg.2012.59.2.141] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
86 Rozette NA, Hellauer CM, Mckee C, Vazifedan T, Gabriel CA, Dice JE, Yokois NU. Evaluation of Rapid vs Standard Infliximab Infusions in the Pediatric Population. Inflammatory Bowel Diseases 2018;24:2007-14. [DOI: 10.1093/ibd/izy093] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
87 Ng SC, Plamondon S, Gupta A, Burling D, Swatton A, Vaizey CJ, Kamm MA. Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for Crohn's perineal fistulas. Am J Gastroenterol. 2009;104:2973-2986. [PMID: 19755971 DOI: 10.1038/ajg.2009.509] [Cited by in Crossref: 115] [Cited by in F6Publishing: 96] [Article Influence: 9.6] [Reference Citation Analysis]
88 Cappello M, Morreale GC. The Role of Laboratory Tests in Crohn's Disease. Clin Med Insights Gastroenterol. 2016;9:51-62. [PMID: 27656094 DOI: 10.4137/cgast.s38203] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 2.4] [Reference Citation Analysis]
89 Day AS, Gulati AS, Patel N, Boyle B, Park KT, Saeed SA. The Role of Combination Therapy in Pediatric Inflammatory Bowel Disease: A Clinical Report from the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;66:361-8. [PMID: 29210919 DOI: 10.1097/MPG.0000000000001850] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
90 Moran GW, Dubeau MF, Kaplan GG, Panaccione R, Ghosh S. Novel concepts in inflammatory bowel disease. British Medical Bulletin 2014;109:55-72. [DOI: 10.1093/bmb/ldt039] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
91 Pillet S, Jarlot C, Courault M, Del Tedesco E, Chardon R, Saint-Sardos P, Presles E, Phelip JM, Berthelot P, Pozzetto B, Roblin X. Infliximab Does Not Worsen Outcomes During Flare-ups Associated with Cytomegalovirus Infection in Patients with Ulcerative Colitis. Inflamm Bowel Dis. 2015;21:1580-1586. [PMID: 25933392 DOI: 10.1097/mib.0000000000000412] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 4.8] [Reference Citation Analysis]
92 Afif W, Loftus EV. Safety Profile of IBD Therapeutics: Infectious Risks. Gastroenterology Clinics of North America 2009;38:691-709. [DOI: 10.1016/j.gtc.2009.07.005] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
93 Fernandes C, Allocca M, Danese S, Fiorino G. Progress with anti-tumor necrosis factor therapeutics for the treatment of inflammatory bowel disease. Immunotherapy 2015;7:175-90. [PMID: 25713992 DOI: 10.2217/imt.14.105] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
94 Lin Z, Bai Y, Zheng P. Meta-analysis: efficacy and safety of combination therapy of infliximab and immunosuppressives for Crohn's disease. Eur J Gastroenterol Hepatol. 2011;23:1100-1110. [PMID: 21971373 DOI: 10.1097/MEG.0b013e32834b9544] [Cited by in Crossref: 33] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
95 Lichtenstein GR. Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment response. Therap Adv Gastroenterol 2013;6:269-93. [PMID: 23814608 DOI: 10.1177/1756283X13479826] [Cited by in Crossref: 51] [Cited by in F6Publishing: 20] [Article Influence: 6.4] [Reference Citation Analysis]
96 Ishida K, Inoue T, Fujiwara K, Sakanaka T, Narabayashi K, Nouda S, Okada T, Kakimoto K, Kuramoto T, Kawakami K, Abe Y, Takeuchi T, Murano M, Tokioka S, Umegaki E, Higuchi K. Clinical effects of adalimumab treatment with concomitant azathioprine in Japanese Crohn’s disease patients. World J Gastroenterol 2013; 19(17): 2676-2682 [PMID: 23674875 DOI: 10.3748/wjg.v19.i17.2676] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
97 Meredith J, Henderson P, Wilson DC, Russell RK. Combination Immunotherapy Use and Withdrawal in Pediatric Inflammatory Bowel Disease-A Review of the Evidence. Front Pediatr 2021;9:708310. [PMID: 34621712 DOI: 10.3389/fped.2021.708310] [Reference Citation Analysis]
98 Jones JL, Kaplan GG, Peyrin-Biroulet L, Baidoo L, Devlin S, Melmed GY, Tanyingoh D, Raffals L, Irving P, Kozuch P, Sparrow M, Velayos F, Bressler B, Cheifetz A, Colombel JF, Siegel CA. Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials. Clin Gastroenterol Hepatol 2015;13:2233-40.e1-2; quiz e177-8. [PMID: 26142167 DOI: 10.1016/j.cgh.2015.06.034] [Cited by in Crossref: 78] [Cited by in F6Publishing: 74] [Article Influence: 13.0] [Reference Citation Analysis]
99 John ES, Katz K, Saxena M, Chokhavatia S, Katz S. Management of Inflammatory Bowel Disease in the Elderly. Curr Treat Options Gastroenterol. 2016;14:285-304. [PMID: 27387455 DOI: 10.1007/s11938-016-0099-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
100 Takeuchi M, Asukata Y, Kawagoe T, Ito N, Nishide T, Mizuki N. Infliximab Monotherapy Versus Infliximab and Colchicine Combination Therapy in Patients with Behçet’s Disease. Ocular Immunology and Inflammation 2012;20:193-7. [DOI: 10.3109/09273948.2012.665124] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
101 Gisbert JP, Barreiro-de Acosta M, Esteve M, García-Sánchez V, Gomollón F, Guardiola J, Hinojosa J, Martín Arranz MD, Minguez M, Taxonera C, Vera I. Physician Perspectives on Unresolved Issues in the Management of Ulcerative Colitis: The UC Horizons Project. Inflamm Bowel Dis 2016;22:583-98. [PMID: 26529561 DOI: 10.1097/MIB.0000000000000617] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
102 Martins CDA, Moss AC, Sobrado CW, Queiroz NSF. Practical Aspects of Proactive TDM for Anti-TNF Agents in IBD: Defining Time Points and Thresholds to Target. Crohn's & Colitis 360 2019;1:otz049. [DOI: 10.1093/crocol/otz049] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
103 Tominaga K, Sugaya T, Tanaka T, Kanazawa M, Iijima M, Irisawa A. Thiopurines: Recent Topics and Their Role in the Treatment of Inflammatory Bowel Diseases. Front Pharmacol 2020;11:582291. [PMID: 33584261 DOI: 10.3389/fphar.2020.582291] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
104 Ordás I, Mould DR, Feagan BG, Sandborn WJ. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther. 2012;91:635-646. [PMID: 22357456 DOI: 10.1038/clpt.2011.328] [Cited by in Crossref: 321] [Cited by in F6Publishing: 281] [Article Influence: 35.7] [Reference Citation Analysis]
105 Bor R, Farkas K, Bálint A, Szucs M, Ábrahám S, Baradnay G, Wittmann T, Szepes Z, Nagy F, Molnár T. Efficacy of combined anti-TNF-alpha and surgical therapy in perianal and enterocutaneous fistulizing Crohn's disease--clinical observations from a tertiary Eastern European center. Scand J Gastroenterol 2015;50:182-7. [PMID: 25384713 DOI: 10.3109/00365521.2014.936033] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
106 Frei P, Biedermann L, Nielsen OH, Rogler G. Use of thiopurines in inflammatory bowel disease. World J Gastroenterol 2013; 19(7): 1040-1048 [PMID: 23467510 DOI: 10.3748/wjg.v19.i7.1040] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
107 施嫣红, 翁韵, 刘占举. 血清英夫利昔单抗浓度检测对炎症性肠病患者疗效的评估价值. 世界华人消化杂志 2015; 23(31): 4946-4953 [DOI: 10.11569/wcjd.v23.i31.4946] [Reference Citation Analysis]
108 Ye BD, Yang S, Shin SJ, Lee KM, Jang BI, Cheon JH, Choi CH, Kim Y, Lee H; IBD Study Group of the Korean Association for the Study of the Intestinal Diseases. Guidelines for the Management of Crohn's Disease. Intest Res 2012;10:26. [DOI: 10.5217/ir.2012.10.1.26] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
109 Gies N, Kroeker KI, Wong K, Fedorak RN. Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort. Aliment Pharmacol Ther 2010;32:522-8. [PMID: 20500733 DOI: 10.1111/j.1365-2036.2010.04380.x] [Cited by in Crossref: 68] [Cited by in F6Publishing: 57] [Article Influence: 6.2] [Reference Citation Analysis]
110 D’Haens GR, Panaccione R, Higgins PD, Vermeire S, Gassull M, Chowers Y, Hanauer SB, Herfarth H, Hommes DW, Kamm M. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011;106:199-212; quiz 213. [PMID: 21045814 DOI: 10.1038/ajg.2010.392] [Cited by in Crossref: 263] [Cited by in F6Publishing: 256] [Article Influence: 23.9] [Reference Citation Analysis]
111 Colombel JF, Jharap B, Sandborn WJ, Feagan B, Peyrin-Biroulet L, Eichner SF, Robinson AM, Mostafa NM, Zhou Q, Thakkar RB. Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy. Aliment Pharmacol Ther 2017;45:50-62. [PMID: 27883215 DOI: 10.1111/apt.13838] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 7.4] [Reference Citation Analysis]
112 Moss AC. Optimizing the use of biological therapy in patients with inflammatory bowel disease. Gastroenterol Rep (Oxf). 2015;3:63-68. [PMID: 25567472 DOI: 10.1093/gastro/gou087] [Cited by in Crossref: 48] [Cited by in F6Publishing: 38] [Article Influence: 8.0] [Reference Citation Analysis]
113 Absah I, Faubion WA. Concomitant therapy with methotrexate and anti-TNF-α in pediatric patients with refractory crohn’s colitis: a case series. Inflamm Bowel Dis. 2012;18:1488-1492. [PMID: 21882301 DOI: 10.1002/ibd.21885] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
114 Rayen J, Currie T, Gearry RB, Frizelle F, Eglinton T. The long-term outcome of anti-TNF alpha therapy in perianal Crohn's disease. Tech Coloproctol 2017;21:119-24. [PMID: 28066859 DOI: 10.1007/s10151-016-1578-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
115 Jani M, Barton A, Warren RB, Griffiths CE, Chinoy H. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology (Oxford) 2014;53:213-22. [PMID: 23946436 DOI: 10.1093/rheumatology/ket260] [Cited by in Crossref: 127] [Cited by in F6Publishing: 109] [Article Influence: 15.9] [Reference Citation Analysis]
116 Kirchgesner J, Lemaitre M, Carrat F, Zureik M, Carbonnel F, Dray-Spira R. Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases. Gastroenterology. 2018;155:337-346.e10. [PMID: 29655835 DOI: 10.1053/j.gastro.2018.04.012] [Cited by in Crossref: 194] [Cited by in F6Publishing: 169] [Article Influence: 64.7] [Reference Citation Analysis]
117 Dignass A, Van Assche G, Lindsay J, Lémann M, Söderholm J, Colombel J, Danese S, D'hoore A, Gassull M, Gomollón F, Hommes D, Michetti P, O'morain C, Öresland T, Windsor A, Stange E, Travis S. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. Journal of Crohn's and Colitis 2010;4:28-62. [DOI: 10.1016/j.crohns.2009.12.002] [Cited by in Crossref: 981] [Cited by in F6Publishing: 872] [Article Influence: 89.2] [Reference Citation Analysis]
118 Beaugerie L, Kirchgesner J. Balancing Benefit vs Risk of Immunosuppressive Therapy for Individual Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2019;17:370-379. [PMID: 30031174 DOI: 10.1016/j.cgh.2018.07.013] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 11.3] [Reference Citation Analysis]
119 Turner D, Levine A, Escher JC, Griffiths AM, Russell RK, Dignass A, Dias JA, Bronsky J, Braegger CP, Cucchiara S, de Ridder L, Fagerberg UL, Hussey S, Hugot JP, Kolacek S, Kolho KL, Lionetti P, Paerregaard A, Potapov A, Rintala R, Serban DE, Staiano A, Sweeny B, Veerman G, Veres G, Wilson DC, Ruemmele FM; European Crohn's and Colitis Organization; European Society for Paediatric Gastroenterology; Hepatology; and Nutrition. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. J Pediatr Gastroenterol Nutr. 2012;55:340-361. [PMID: 22773060 DOI: 10.1097/mpg.0b013e3182662233] [Cited by in Crossref: 251] [Cited by in F6Publishing: 66] [Article Influence: 31.4] [Reference Citation Analysis]
120 Qiu Y, Chen BL, Mao R, Zhang SH, He Y, Zeng ZR, Chen MH. Early Thiopurines Versus Conventional Step-Care Therapy for Modifying the Disease Course of Early Crohn's Disease: A Tertiary Referral Center Cohort Study. Medicine (Baltimore) 2015;94:e1148. [PMID: 26252273 DOI: 10.1097/MD.0000000000001148] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
121 Nasuno M, Miyakawa M, Tanaka H, Motoya S. Short- and Long-Term Outcomes of Infliximab Treatment for Steroid-Refractory Ulcerative Colitis and Related Prognostic Factors: A Single-Center Retrospective Study. Digestion 2017;95:67-71. [PMID: 28052276 DOI: 10.1159/000452459] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
122 Nielsen OH. New strategies for treatment of inflammatory bowel disease. Front Med (Lausanne). 2014;1:3. [PMID: 25685754 DOI: 10.3389/fmed.2014.00003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
123 Mottet C, Schoepfer AM, Juillerat P, Cosnes J, Froehlich F, Kessler-brondolo V, Seibold F, Rogler G, Vavricka SR, Michetti P. Experts Opinion on the Practical Use of Azathioprine and 6-Mercaptopurine in Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 2016;22:2733-47. [DOI: 10.1097/mib.0000000000000923] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 3.2] [Reference Citation Analysis]
124 Thomson AB, Gupta M, Freeman HJ. Use of the tumor necrosis factor-blockers for Crohn's disease. World J Gastroenterol 2012; 18(35): 4823-4854 [PMID: 23002356 DOI: 10.3748/wjg.v18.i35.4823] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
125 Bressler B, Siegel CA. Beware of the swinging pendulum: anti-tumor necrosis factor monotherapy vs combination therapy for inflammatory bowel disease. Gastroenterology. 2014;146:884-887. [PMID: 24576727 DOI: 10.1053/j.gastro.2014.02.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
126 Devlin SM, Cheifetz AS, Siegel CA. Patient-Specific Approach to Combination Versus Monotherapy with the Use of Antitumor Necrosis Factor α Agents for Inflammatory Bowel Disease. Gastroenterology Clinics of North America 2012;41:411-28. [DOI: 10.1016/j.gtc.2012.01.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
127 Kantasiripitak W, Verstockt B, Alsoud D, Lobatón T, Thomas D, Gils A, Vermeire S, Ferrante M, Dreesen E. The effect of aging on infliximab exposure and response in patients with inflammatory bowel diseases. Br J Clin Pharmacol 2021;87:3776-89. [PMID: 33604964 DOI: 10.1111/bcp.14785] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
128 Nielsen OH, Seidelin JB, Munck LK, Rogler G. Use of biological molecules in the treatment of inflammatory bowel disease. J Intern Med. 2011;270:15-28. [PMID: 21241384 DOI: 10.1111/j.1365-2796.2011.02344.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
129 Barnes EL, Goldin A, Winter RW, Collins E, Cao B, Carrellas M, Crowell AM, Korzenik JR. Sequential Combination Therapy Versus Monotherapy: A Lack of Benefit in Time to Inflammatory Bowel Disease-Related Surgery. Dig Dis Sci 2016;61:3261-9. [PMID: 27639871 DOI: 10.1007/s10620-016-4302-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
130 Fischer M, Helper DJ, Chiorean MV. Myeloproliferative disorders in patients with inflammatory bowel disease on anti-TNF-α therapy: Report of two cases and review of the literature. Inflammatory Bowel Diseases 2011;17:674-5. [DOI: 10.1002/ibd.21291] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
131 Reich K, Wozel G, Zheng H, van Hoogstraten H, Flint L, Barker J. Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2). British Journal of Dermatology 2013;168:1325-34. [DOI: 10.1111/bjd.12404] [Cited by in Crossref: 73] [Cited by in F6Publishing: 64] [Article Influence: 9.1] [Reference Citation Analysis]